Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
Status:
Unknown status
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This is a monocentric, prospective phase II trial addressing safety and capability to prevent
grade-4 Chemotherapy-induced Thrombocytopenia (CIT) of romiplostim in patients with NHL.